ICMR, Panacea Biotec initiate first dengue vaccine Phase 3 clinical trial in India with DengiAll - Video
|
Overview
The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever Phase 3 clinical trial for a dengue vaccine in India. This landmark trial will evaluate the efficacy of India's indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec. The first participant in this trial was vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak.
Commenting on this milestone, Union Minister of Health & Family Welfare, Shri J.P. Nadda, said, “The initiation of this Phase 3 clinical trial for India's first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India's capabilities in vaccine research and development. Through this collaboration between ICMR and Panacea Biotec, we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector.”
For more information, click on the link below:
Speakers
With a graduation in Journalism and Mass Communication from Amity University, Yakshi Chugh embarked on a journey to explore the dynamic intersection of media and healthcare. In 2024, she joined Medical Dialogues, driven by a passion to enhance healthcare journalism and deliver insightful, impactful content to readers.
